What is GANX (GANX) stock price today?

GANX (GANX) is currently trading at $1.73, down 6.99% today.

What is GANX P/E ratio?

GANX's P/E ratio is -2.70. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GANX return on equity (ROE)?

GANX's return on equity (ROE) is -105.26%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GANX's market cap?

GANX has a market capitalization of $73.79M.

NASDAQ · Biotechnology

GANX (GANX) Stock

$1.73 -6.99% NASDAQ: GANX Healthcare

Valuation

Metric	Value
Price	$1.73
Market Cap	$73.79M
P/E Ratio	-2.70
P/B Ratio	3.70
P/S Ratio	0.00
EPS (TTM)	$-0.61
52-Week High	$4.34
52-Week Low	$1.41
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-105.26%
ROA	-86.96%
ROCE	-100.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.02
Current Ratio	7.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-14.0M	$-18.0M	$-22.0M	$-20.0M	$-19.0M
Net Profit	$-14.0M	$-18.0M	$-22.0M	$-20.0M	$-20.0M
EPS	$-1.37	$-1.48	$-1.71	$-0.89	$-0.61
Op Margin	-10323.6%	-13402.5%	-40328.3%	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$39.0M	$24.0M	$19.0M	$12.0M	$23.0M
Total Liabilities	$4.0M	$5.0M	$6.0M	$5.0M	$4.0M
Cash	$37.0M	$7.0M	$12.0M	$10.0M	$21.0M
Borrowings	$2.0M	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO MT Newswires · Jul 16, 2026 Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update GlobeNewswire · Jul 16, 2026 Why Is GANX Stock Rallying 22% After Hours? Stocktwits · Jun 29, 2026 Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease MT Newswires · Jun 29, 2026 Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-12.0M	$-15.0M	$-19.0M	$-19.0M	$-18.0M
Investing Cash Flow	$0	$-15.0M	$10.0M	$5.0M	$0
Financing Cash Flow	$-1.0M	$0	$0	$0	$0
Net Cash Flow	$29.0M	$-30.0M	$4.0M	$-1.0M	$10.0M
Free Cash Flow	$-12.0M	$-15.0M	$-19.0M	$-19.0M	$-18.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-27.52%
Quick Ratio	4.69
Interest Coverage	—
Return 1Y	-2.65%
Return 3Y	-62.73%
Return 5Y	-82.51%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACET	$8.30	+1.22%	-0.46	$77.59M	0.00%
ADAGAdagene Inc.	$3.67	+1.66%	-7.78	$138.17M	0.00%
CRVO	$2.56	-3.76%	-1.09	$23.70M	0.00%
FBIO	$2.67	-3.61%	0.91	$88.69M	0.00%
LITS	$0.91	-2.31%	-0.35	$30.88M	0.00%

About GANX

GANX is led by CEO Gene Mack, employs 23 people, headquartered in US, publicly traded since 2021.

GANX stock trades at $1.73 with a market capitalization of $73.79M. The stock is valued at a price-to-earnings (P/E) ratio of -2.70, price-to-book of 3.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.41 and $4.34, and currently trades 60.1% below its 52-week high.

On profitability, GANX generates a return on equity (ROE) of -105.26%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides